Form 4: Vaxcyte CFO Andrew Guggenhime Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Vaxcyte's President and CFO, Andrew Guggenhime, exercised stock options and sold shares on January 21, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- Andrew Guggenhime, President and CFO of Vaxcyte, Inc., executed a stock option to acquire 8,000 shares at $5.35 per share on January 21, 2025.
- On the same day, Mr. Guggenhime sold a total of 7,999 shares in multiple transactions at weighted average prices ranging from $86.084 to $87.7 per share.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on May 17, 2024.
- Following these transactions, Mr. Guggenhime directly owns 109,491 shares of Vaxcyte common stock and 254,827 stock options.
Sentiment
Score: 5
Explanation: The document reflects routine insider trading activity under a pre-arranged plan, which is neither positive nor negative for the company's overall outlook.
Industry Context
This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to manage their stock sales and avoid accusations of insider trading.
Comparison to Industry Standards
- The use of 10b5-1 trading plans is a standard practice among executives at publicly traded companies, including those in the biotechnology sector like Vaxcyte.
- Similar filings are regularly made by executives at companies like Moderna, BioNTech, and Novavax, reflecting routine stock transactions under pre-arranged plans.
- The reported sale prices are within the typical range for stock transactions of this nature, and the volume of shares sold is not unusual for an executive's trading activity.
Stakeholder Impact
- The transactions have a minimal impact on shareholders as they are part of a pre-arranged trading plan and do not indicate a change in the executive's confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 05/17/2024 | Date the Rule 10b5-1 trading plan was adopted. |
| 01/21/2025 | Date of the stock option exercise and share sales. |
| 01/22/2025 | Date the Form 4 was signed. |
| 05/11/2030 | Expiration date of the stock options. |
Keywords
Vaxcyte, Andrew Guggenhime, stock options, share sales, Form 4, Rule 10b5-1, insider trading, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.